Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Loyola physician sheds light on common and painful viral infection, shingles

Loyola physician sheds light on common and painful viral infection, shingles

New Gamma Knife stereotactic radiosurgery reduces severe facial pain caused by nerve disorder

New Gamma Knife stereotactic radiosurgery reduces severe facial pain caused by nerve disorder

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

New drug treatment effective against chronic pain caused by nerve damage post shingles

New drug treatment effective against chronic pain caused by nerve damage post shingles

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Depomed reports financial results for third quarter 2013

Depomed reports financial results for third quarter 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

LCH hosts international dental teaching symposium at Jessie Trice Community Health Center

LCH hosts international dental teaching symposium at Jessie Trice Community Health Center

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

FDA accepts NDA for MNK-795 oral formulation

FDA accepts NDA for MNK-795 oral formulation

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Orlando Health and UF health partner to expand neurosurgery program

Orlando Health and UF health partner to expand neurosurgery program

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.